NEWS


ALLERGY PODINAR SERIES


IFAN (Irish Food Allergy Network) invites you to attend a new allergy ‘podinar’ series.


Join leading allergy experts from across Ireland and tune in to practical discussions on allergy management. There’s no formal struc ture, no slides and it’s all live - what could possibly go wrong? Each session will focus on a different topic, ranging from common allergy issues in the first year to anaphylaxis management and community care. Come along to our next session on Tuesday 30 March with Dr John Fitzsimons and Professor Basil Elnazir discussing ‘Respiratory Allergies’, hosted by Dr Aideen Byrne.


Register here: www. nutricia.wavecast.io/ifan-allergy/respiratory-allergies


For more information about upcoming events in this series and a full line-up of our speakers, please visit the news and events page on our website at www.nutricia.ie or email events.ireland@nutricia.com


FUNDING OF £204,000 TO PROJECTS


Community Development and Health Network (CDHN) has announced that funding has been approved for 17 successful applicants in the latest round of Building the Community-Pharmacy Partnership (BCPP) Level 2 funding.


The groups to benefit from £12,000 each are as follows: • Mid East Antrim Agewell Partnership (MEAAP), Ballymena • Mind Your Mate and Yourself (MYMY), Newcastle • Centred Soul, Newry • The Right Key, Lisburn • Cornabracken - Afterschool CIC, Omagh • Voices Women's Group, Belfast • Tullygarley & District Residents' Association, Ballymena • Birthwise, Newry • Giggles Afterschool Ltd, Newry • Hillstown Rural Community Group/Grange Cross Community Association, Randalstown


• Respect Youth Project, Newry • An Tobar CIC, Silverbridge, Newry • Milburn Community Association, Coleraine • Futureproof, Banbridge • Waterside Women's Centre, Derry • Fermanagh Sports & Cultural Awareness, Ballinamallard • Cullybackey Community Partnership, Cullybackey


Applications for Level 2 funding close on 25 March. If you would like some support with a potential project, please contact a member of the BCPP team on 028 3026 4606 or email bcpp@cdhn.org


PILL AVAILABLE FROM PHARMACIES: CONSULTATION


The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on the reclassification of two progestogen-only contraceptive pills containing desogestrel. This is the first time such a change has been considered, making it important that the public’s views are heard.


The consultation affects two products containing desogestrel; Lovima 75 microgram film-coated tablets and Hana 75 microgram film-coated tablets. Lovima and Hana are both oral contraceptives for continuous use to prevent pregnancy in those of childbearing age.


‘Every response received will help us gain a better picture of whether people think the contraceptive pill with desogestrel should be available over the counter,’ said Dr Sarah Branch, Director of Vigilance and Risk Management of Medicines at the MHRA. ‘We hope to hear from as many people and women’s groups as possible.’


Contraceptive pills containing desogestrel will still be available on prescription from GPs and sexual health clinics.


NEW REASEARCH AT QUB


Researchers from the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast are leading a new international consortium, funded by Cancer Research UK, which aims to determine better ways to treat patients diagnosed with the earliest stages of bowel cancer.


The consortium includes a multi-disciplinary team of research scientists and clinicians from across the UK and Europe and is led by Dr Philip Dunne, Molecular Pathologist at the centre.


Survival rates for patients diagnosed at the earliest stage of bowel cancer are in excess of 95 per cent, but only in a small proportion of cases, screening identifies patients with highly aggressive tumours.


‘This work,’ says Dr Keara Redmond, Researcher from the Patrick G Johnston Centre for Cancer Research, Scientific Specialist and Project Manager in Belfast, who will lead the molecular profiling, said: ‘will provide us with the largest known collection of early-stage bowel cancer samples, which will serve as an important resource for scientists worldwide to investigate this disease. This will enable the field to identify changes in tumour DNA, both mutations and gene activation, associated with aggressive disease.”


NEW LOOK PIF MAG! 6 pharmacyinfocus.com


Register to receive regular FREE ezines pharmacyinfocus.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48